New combo therapy offers hope for patients with stubborn low platelet disorder

This study tests a combination of two drugs, romiplostim and rituximab, in about 30 adults with primary immune thrombocytopenia (ITP) whose condition did not improve with standard oral treatments. Participants receive weekly injections of romiplostim and four weekly infusions of rituximab. The goal is to see if this combo can safely raise platelet counts and reduce bleeding symptoms.